|
KMID : 0941820140240040255
|
|
Korean Journal of Clinical Pharmacy
2014 Volume.24 No. 4 p.255 ~ p.264
|
|
|
Study of the Drugs Prescribed on Alzheimer’s Disease: from the Insurance Claims Data of Korea National Health Insurance Service
|
|
Kim Jung-Eun
Lee Jong-Hyuk
Jeong Ji-Hoon
Kang Min-Ku
Bang Joon-Seok
|
|
|
Abstract
|
|
|
Objective: The aims of this study are to investigate the total volume of prescribed medicines against Alzheimer’s disease
(AD) and the trends of usage by analyzing the claims-data from the Korea National Health Insurance Service.
Method: The demographic and claims-data were included the major AD treating medicines such as donepezil, alantamine, rivastigmine and memantine, and analyzed during the period of 2010~2012. The assessing criteria were gender, age, habitation, types of medical institution, code of ingredients, outcomes of treatment, volume and amount of claims, and the numbers of patients with dementias. After trimming the data, it were analyzed by the market size, demographic traits, characteristics of medical service, characteristics of each anti-AD medicine, etc.
Results: Among the chosen 4 medicines, donepezil had the top prescription volumes. Most prevalent prescribing preparations of donepezil were conventional types. However, among the non-conventional types, oro-dispersible formulation is the fast increasing one in both volume and growth rate. This specialized preparations to improve both toleration and adherence, tend to being prescribed generally at the tertiary medical institutions. While the younger patients with mild-to-moderate AD mostly treated by expensive medicines in resident at the tertiary hospitals, the rest older patients with severe AD have been treated non-expensive one at long-term care facilities.
Conclusion: AD is a chronic illness therefore, long-term use of therapeutic medications are highly important. If an anti-AD treatment was applied steadily in the earlier stages, it would be achieved not only improving the quality of life of patient but also reducing the expenses in the medical and nursing cares. As the socioeconomical impacts of AD is expanding, healthcare professionals need to aware the importance of pharmacotherapy and to improve sociopolitical fundamentals.
|
|
|
KEYWORD
|
|
|
Alzheimer’s disease, claims data, donepezil, galantamine, rivastigmine, memantine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|